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 Osteoporosis is determined by decreased bone strength that increases the threat of 
fractures. The aim of this study was to evaluate the effects of pentoxifylline (PTX) and 
alendronate (ALN), on the stereological parameters, and gene expression in callus of fracture 
in an experimental rat model of ovariectomy-induced osteoporosis (OVX). The OVX was 
induced in 90 female rats. Fourteen weeks later, a complete fracture on the right femur was 
made. Rats were divided into five groups: 1) control: no treatment; 2) sham: received daily 
distilled water; 3) daily 3.00 mg kg-1 ALN subcutaneously (SC); 4) daily 200 mg kg-1 PTX (SC) 
and 5) daily PTX (SC) + ALN (same doses). The osteoclast count was significantly lower in all 
treatment groups, at 21 and 56 days post-surgery, compared to the control and sham groups. 
The PTX significantly increased total callus volume at 21 and 56 days post-surgery, compared 
to the other groups. The PTX+ALN treatment significantly increased both cortical bone 
volume on day 21, and osteocyte and osteoblast numbers on day 56, compared to the control 
and sham groups. It can be concluded that PTX and ALN have antiresorptive effects, in OVX 
rats. Also, PTX has increased the extracellular matrix on both 21 and 56 days after surgery, 
compared to the other groups. PTX+ALN elevated cortical bone volume on day 21, and 
osteocyte and osteoblast numbers compared to the control and sham groups on day 56.  
© 2019 Urmia University. All rights reserved. 
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شوم رد نادمخت نتشادرب زا یشان زوروپوئتسا رد یگتسکش مایتلا رب تینوردنلآ و نیلیفیسکوتنپ تارثاییارحص یاه 
 هدیکچ 
اوختسا تردق شهاک اب ناوختسا یکوپ رطخ هک نیگتسکشیم شیازفا ار یناوختسا یاه یبایزرا رضاح هعلاطم زا فده .تسا هارمه ،دهد نیلیفیسکوتنپ تارثا(PTX) ،آ تینوردنل(ALN) رب  یاهریغتم
لاک رد نژ نایب زین و کیژولویرتساسو  یبرجت لدم رد یگتسکشناوختسا یکوپ  زا یشان تشادربنادمخت(OVX)  ییارحص شوم رد .دوبرد 09 شوم  ییارحص دش هتشادرب نادمخت و41  کی نآ دعب هتفه
تسار نار ناوختسا رد لماک یگتسکش .دیدرگ داجیا شوم اهجنپ هب  :دندش میسقت هورگ4) دهاش ،نامرد نودب :2)  ،رطقم بآ هنازور تفایرد :مش3) هنازور تفایرد 99/3 یلیم مرگ رب مرگولیک ALN ،1)  تفایرد
هنازور 299 یلیم مرگ رب مرگولیک PTX ،5) تفایرد هنازور PTX + ALN  .)زود نامه(تسلاکوئتسا دادعت یاهزور رد 24  و55 هورگرد یحارج دعب ینامرد یاهبینعم روط رتمک رادزا هورگ.دوب مش و دهاش یاه 
نیلیفیسکوتنپ هبینعم روطلاک لک مجح رادسو هورگ رگید اب هسیاقم رد ار یناوختسازفا اهداد شیا. PTX+ALN هبینعم روطتسلابوئتسا دادعت راداهتیسوئتسا و اه  زور رد55  اب هسیاقم رد ار یرشق ناوختسا مجح و
هورگ رد مش و دهاش یاه زور24  شیازفادادهکدوش یم یریگ هجیتن . PTX ،ALN شوم رد یاهOVX ، دجاو یبذج دض تارثادنشاب یم. ،هولاعب نیلیفیسکوتنپ یلولس جراخ سکیرتام  رد ار24  و55 زور  زا دعب
یحارج  رگید اب هسیاقم ردهورگزفا اهداد شیا .PTX+ALN  زور رد ار یرشق ناوختسا مجح24 زفا دادعت و داد شیاتسلابوئتساتیسوئتسا و اههورگ اب هسیاقم رد ار اهیاه  رد مش و دهاش55 درب لااب زور. 
:یدیلک یاه هژاو رب ،یگتسکش مایتلا ،یژولوئرتساشنکاو ، ناوختسا یکوپ ،نادمخت تشاد هریجنزیا یعقاو نامز رد زارمیلپ 
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Introduction 
 
Osteoporosis (OP) is characterized as a decline in the 
volume of bone mass density and the derangement of 
bone micro construction, resulting in a global deficiency in 
bone strength, which consequently increases the risk of 
fractures.1 The OP is one of the most prevalent chronic 
illnesses in the US and all over the world. The most common 
complication of OP is the fracture, which has a significant 
adverse effect on the quality of life of the patients. 
Particularly in elderly people, it can trigger a series of events, 
which can eventually lead to death.2 The OP is a rising 
issue in the US that influences 10 million patients nation-
wide,3 causing two million fractures annually with the 
financial burden of approximately $19 billion per year.4  
Menopause is accompanied by lower estrogen levels 
and increases the risk of OP in women.5 In a normal body, 
osteoclast (OC) and osteoblast cells coordinate closely to 
maintain bone integrity. The OP is related to the huge 
increase in bone resorption triggered by amplifying OC 
counts (due to stimulated OC production and decreased 
OC death) and also by increased OC activity.6 
Inadequate bone mass and derangement of the bone 
structure caused by OP, increases the risk of a fragility 
fracture of the bone, in comparison with the normal bone. 
Fracture healing in the elderly who suffer from OP remains 
a complex clinical challenge.7 Animal studies 
demonstrated that pharmacological interventions can 
accelerate fracture healing, offering an essential adjunct to 
bone fracture management.8  
Bisphosphonates (BPs) have been used for the treat-
ment of OP for many years.9 Animal experiments have 
shown that alendronate (ALN) administration prevents 
bone resorption and has a positive effect on fracture healing, 
without any adverse effects on bridging, bone strength, or 
mineralization in adult dogs.10 Long-term ALN treatments 
suppressed remodeling and consequently increased the 
degree of mineralization of bone.11 Moreover, ALN 
treatment increased bone strength via the distinctive 
effect on bone mass and quality.12 In addition, ALN might 
delay the process of intracortical bone turnover in rats,13 
and displays a positive outcome on bone mineral density 
(BMD) in the metaphyseal fracture healing.14 In 
ovariectomy-induced osteoporosis (OVX) rats, ALN had a 
favorable effect on the biomechanical parameters of the 
callus, but delayed callus turnover by inhibiting the trans-
formation of woven bone into lamellar bone.15 In humans, 
administration of BPs alone, after a fracture happens does 
not seem to have a marked effect on the bone defect. 
Rarely, the atypical fractures and delayed bone repair 
process have been reported in the patients with long term 
use of BP.9 Clearly, some pharmacological materials have a 
negative influence on the fracture healing process; thus, 
sometimes a minimal alteration in medications, used by 
the patient can lead to a better result.16  
 Several investigations have demonstrated that 
pentoxifylline (PTX) improves fracture healing in healthy 
animals and patients.17-22 We hypothesized that PTX can 
be used as a potential therapeutic medicine for treating 
bone defect, as established by several investigations.17-22  
Recently, Vashghani Farahani et al. examined the 
effects of the administration of 200 mg kg-1 PTX on the 
remodeling phase of a complete bone fracture in OVX rats. 
The results demonstrated increased biomechanical 
properties of callus in PTX-treated rats, compared to the 
control OVX animals.22 
In this study, we evaluated the effects of PTX and ALN 
alone and in combination, on stereological parameters, 
and the gene expression of insulin-like growth factor I 
(IGF-I), bone morphogenetic protein BMP-2 and BMP-7, 
and Wnt10b, in callus of fracture in an experimental rat 
model of OVX. The results of the current study could be 
utilized to develop clinical trials, which eventually could 
improve the fracture-healing process in patients with OP.  
 
Materials and Methods 
 
Animals and study design. Ninety adult female 
Wistar rats, 20 weeks old and weighing 241.60 ± 11.76 g 
(mean ± SD), were kept in a standard animal house and 
weighed regularly on a weekly basis during the 
experiment. Firstly, OVX was induced in all rats by 
removing both ovaries. Then a complete fracture was 
created in the midshaft of the right femur. The rats were 
divided into five groups (18 animals in each) including: 
Group 1) control: no treatment; group 2) sham: received 
daily distilled water subcutaneously (SC); group 3) daily 
3.00 mg kg-1 ALN (Alborz Darou, Tehran, Iran, SC); group 
4) daily 200 mg kg-1 PTX (Sigma-Aldrich, St. Louis, USA) 
divided into two doses of 100 mg kg-1 intraperitoneally at 
9:00 AM and 100 mg kg-1 SC at 5:00 PM, and group 5) 
PTX+ALN (both SC, same doses). Finally, the rats were 
euthanized at different time points (after 21, and 56 days 
for stereological study, and 35 days for gene expression 
test), and the calluses were dissected and submitted for 
stereological and gene expression analysis. The protocol 
was evaluated and approved by the institutional Medical 
Ethics Commission of the first author’s institute (No: 1392-
1-115-1159). 
Ovariectomy. The technique has been previously 
described in details.23 Briefly, under general anesthesia 
and aseptic conditions, two paravertebral skin incisions 
were made and ovaries were removed. After removing the 
bilateral ovaries, the wounds were closed. Rats were kept 
for 14 weeks in order to establish OP.23  
Fracture model, treatments and sampling. The 
technique was explained thoroughly in our previous 
study.23 Under general anesthesia and aseptic conditions, 
one incision was made over the right thigh to expose the 
femur. Three to five partial transversal standardized 
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osteotomies were made with a low-speed drill in each 
femur, then the osteotomy site was broken manually and 
the femur was divided into two parts. The bone was 
stabilized with internal fixation. Fixation was performed 
intramedullary, using a stainless wire (1.00 mm diameter). 
Fracture fragments were contacted and stabilized. A 
distance of 3.00 mm (gap) was maintained between the 
edges of fractures, constant in the entire population of rats. 
Wires were cut on the surface of the femur`s intercondylar 
groove to avoid restricted motion in the knee joint. Muscle 
tissue was sutured with 4-0 catgut (Supa, Tehran, Iran) 
and the skin was sutured with 4-0 nylon reversed cutting 
sutures (Supa). The unrestricted activity was allowed after 
recovery from anesthesia. The rats received the daily 
treatments as mentioned before. At first, we have 
performed a dose-response study on fracture healing in 
healthy rats and 200 mg kg-1 of PTX was chosen as the 
optimum dose for fracture healing in rats in the current 
study.16 Prior to surgery, all rats received 20.00 mg kg-1 
ibuprofen (Emad Darman Pars Co., Tehran, Iran) orally 
and then every 8 to 12 hr for five days after surgery. On 
the other hand, in many studies, authors treat fracture 
healing in osteoporotic models for two months,22,24 
accordingly, PTX and ALN treatments were performed for 
eight weeks. The rats were euthanized with an overdose of 
150 mg kg-1 ketamine (Roche Diagnostics, Mannheim, 
Germany) and 15 mg kg -1 diazepam (Caspian Tamin 
Pharmaceutical Co., Rasht, Iran) and placed in a CO2 
chamber on days 21 and 56 post-operation for stereological 
examination, and on day 35 for gene expression analysis. 
Thus, the callus of some rats was submitted for histological 
and stereological examination, and the callus of other rats 
was submitted for gene expression analysis. We have 
studied histological examinations at anabolic (day 21), and 
catabolic (day 56) phases of fracture healing.24-27 This time 
was chosen because, according to our preliminary 
experiment and the other study,28 fracture healing was in 
progress, although not complete, and peripheral resorption 
of the outer callus should not occur. Thus, it seems that the 
expression of the genes of interest in our fracture healing 
model on day 35 was at the optimized state. 
Measurement of the bone volumes. All procedures 
were explained in details in our previous publications.23,29 
The fractured bones were fixed in formalin saline and 
decalcified in formic acid for three weeks. The sections of 
5- and 15 μm thickness from the specimens were cut 
serially in the callus area, then they were embedded in 
paraffin. The sections were stained with hematoxylin and 
eosin (H & E), subsequently 15 sections were randomly 
selected for stereological examination. The bone defects 
were evaluated, using a light microscope connected to a 
camera and a projecting microscope. All volumes (V), 
including total volume of callus (mm3), trabecular bone 
volume (mm3), and cortical bone volume (mm3) were 
calculated, using the Cavalieri method:  
 
 V= t × (Σp × a/p) 
where, Σp is the total of points, hitting a callus section, 
a/p is the area associated with each point, and t is the 
distance between the sampled sections.23,29  
Estimation of the number of bone cells using 
dissector method. Numerical density of cells was 
calculated by the following formulation:  
Nv = ΣQ [(h × aƒ-1 × Σp) × (t /BA)]-1 
where, ΣQ is the number of cells (103) in all dissectors, h 
is the height of the optical dissector, aƒ-1 is the area of 
the counting frame, Σp is the total number of counted 
frames, BA is the microtome block advance to cut the 
block (25 μm), and t is the mean of the final section 
thickness (20 μm). The formula for the total number (N) 
of bone cells: 23,29 
N = Nv ×Vfinal 
RNA extraction and real time (RT)-PCR. RNA 
extraction and RT-PCR techniques were described in 
details in our previous publication.24 The total RNA was 
extracted, using Trizol reagents (Invitrogen, Carlsbad, 
USA) with the aid of a tissue lyser (Qiagen GmbH, 
Hilden, Germany). The cDNA synthesis was performed, 
using the Revert Aid First Strand cDNA synthesis kit 
(Fermentas, Vilnius, Lithuania). The expression of IGF-I, 
BMP-2, BMP-7 and Wnt10b genes were monitored by 
real-time RT-PCR procedure, using the SYBR Green PCR 
Master Mix (Takara Bio Inc., Kusatsu, Japan). The mRNA 
level of candidate genes were normalized by the signal 
for 18S ribosomal RNA (rRNA) and control group. The 
primers used to amplify cDNA are shown in Table 1. For 
each rat, three replicates were produced for each target 
gene (of IGF-I, BMP-2 and BMP-7, and Wnt10b).29-31  
Statistical analysis. All data were expressed as 
mean ± standard deviation of the mean (SD). 
Differences between treatment groups with normal 
distribution of data were tested by one-way analysis of 
variance (ANOVA), followed by least significant 
difference (LSD) in SPSS (version 20.0; IBM, Chicago, 
USA). Body weight analysis was performed, using 
Student t-test. The p value less than 0.05 was 
considered significant. 
 Table 1. Primers of the studied genes for RT-PCR. 
Gene Primer sequences 
Length of PCR 
products 
IGF1  F: GGAACATAAGGCACGCTGAAC 
88 
IGF1 R: TGAGGAAGCAGGTAGATGGTGA 
BMP2 F: AGAAGCCAGGTGTCTCCAAGA 
222 
BMP2 R: CCACATCACTGAAGTCCACATACA 
BMP7 F: GGTGGTCAACCCTCGGCACA 
109 
BMP7 R: CTGGGGTCCATGCCGTCCAA 
Wnt10b F: GCTTCGGGCCAAGTTGTTGC 
125 
Wnt10b R :CACCCCATTCCCACGTGTCC 
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Results 
 
Stereological examination. The light microscopic 
slides of healing tissue and bone callus in the examined 
groups on days 21, and 56 are shown in Figures 1 and 2. The 
stereological examinations are presented in Figures 3 to 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Micrographs of the repairing tissues and bone callus and 
representative histology of the examined groups on day 21 after 
surgery (H & E, Scale bar = 100 µm). A) First group, OVX, control: 
no treatment; B) second group, OVX, sham: received daily-
distilled water; C) third group, OVX, daily ALN; D) fourth group, 
OVX, daily PTX and E) fifth group OVX, PTX+ALN. F) Osteoblast 
(OSB), Osteocyte (OS), Osteoclast (OSC) was shown in healing 
tissue. T: Trabecular bone, BM: Bone Marrow, CB: Cortical bone.  
 
Stereological results of Day 21. Bone callus volume 
of the PTX group was significantly higher than the ALN, 
sham, control, and PTX+ALN groups (p < 0.001), (Fig. 3A). 
The ALN, and PTX+ALN groups showed a significant 
increase in trabecular bone volume, compared to the sham 
group (p < 0.01), (Fig. 3B). There was a significant increase 
in cortical bone volume of PTX+ALN group than sham and 
control groups (p < 0.05), (Fig. 3C).  
Stereological results on day 56. The PTX+ALN group 
showed a significant increase osteocyte numbers compared 
to the PTX and sham groups according to ANOVA (p > 
0.05) and LSD (both p < 0.05), (Fig. 4A). The PTX+ALN 
showed significantly increased in osteoblast number, 
compared to the ALN, sham, and control groups according 
to ANOVA (p > 0.05) and LSD, (p < 0.01), (p < 0.05), (p < 
0.05), respectively, (Fig. 4B). All treatment groups showed 
a significant decrease in osteoclast number, compared to 
the control and sham groups (p < 0.001), (Fig. 4C).  
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2. Micrographs of the repairing tissue and bone callus and 
representative histology of the study groups on day 56 after 
surgery, (H & E, Scale bar = 100 µm). A) First group, OVX, 
control: no treatment; B) second group, OVX, sham: received 
daily distilled water; C) third group, OVX, daily ALN; D) fourth 
group, OVX, daily PTX and E) fifth group OVX, PTX+ALN. F) 
Osteoblast (OSB), Osteocyte (OS), Osteoclast (OSC) was shown 
in healing tissue. T: Trabecular bone, BM: Bone Marrow, CB: 
Cortical bone, FT: Fibrous tissue. 
 
The PTX group showed a significant increase 
regarding bone callus volume compared to the sham, 
ALN, control and PTX+ALN groups (p < 0.01), (Fig. 5A). 
The PTX group showed a significant decrease in terms 
of trabecular bone volume compared to the control and 
PTX+ALN groups (p < 0.05), (Fig. 5B). All treatment 
groups showed a significant decrease in osteoclast 
number compared to the control and sham groups (p < 
0.001). Also, the ALN group showed a significant 
decrease in osteoclast number compared to the PTX 
group (p < 0.05), (Fig. 5C). 
RT-PCR results. The ALN group demonstrated a 
significant increase in IGF-I expression (43.90 ± 9.90), 
compared to the PTX, PTX + ALN and sham groups (p < 
0.001), (Fig. 6A). The ALN group demonstrated a 
significant increase in BMP-2 expression (20.30 ± 7.40), 
compared to the PTX, PTX+ALN and sham groups (p < 
0.01), (Fig. 6B). The ALN group demonstrated a significant 
increase in BMP-7 expression (37.0 ± 14.70), compared to 
the PTX, PTX+ALN and sham groups (p < 0.01), (Fig. 6C). 
The ALN group demonstrated a significant increase in 
Wnt10b expression (81.60 ± 32.50), compared to the PTX, 
PTX+ALN and sham groups (p < 0.05), (Fig. 6D). 
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Discussion 
 
It was found that PTX, ALN, and PTX+ALN had a 
significant inhibitory effect on osteoclast numbers, 21 and 
56 days post-surgery, compared to the control and sham 
groups in OVX rats. The primary target cell of BPs is the 
osteoclast.30 It seems that a combination of ALN and PTX 
have an inhibitory effect on osteoclast numbers. The 
primary target cell of BPs is the osteoclast. BPs bind to the 
bone surface and are ‘ingested’ by osteoclasts during 
active bone resorption and induced apoptosis in a short- 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
term period.32 Combination of ALN and PTX might inhibit 
osteoclast recruitment by acting on osteoblast lineage cells 
in a long-term period.33  
The findings of the present study were in agreement 
with the findings of Kinoshita et al. who reported that PTX 
significantly increased both cortical and trabecular bone 
volumes in healthy animals.34 They reported an improved 
bone formation and the antiresorptive effects developed 
by the administration of PTX.34 They also suggested that 
PTX administration did not increase and differentiate the 
hemopoietic osteoclast pioneers, but PTX affected the 
 
Fig. 3. Mean ± SD of A) bone callus volume, B) trabecular bone volume, and C) cortical bone volume of the examined groups, using 
ANOVA, on day 21. * p < 0.05, ** p < 0.01, *** p < 0.001. 
Fig. 4. Mean ± SD of A) osteocytes, B) osteoblasts, and C) osteoclasts number in different groups, using ANOVA, and LSD tests on 
day 56, * p < 0.05, ** p < 0.01, *** p < 0.001. 
Fig. 5. Mean ± SD of A) bone callus volume, B) trabecular bone volume and C) number of osteoclasts of the study groups, using 
ANOVA, and LSD tests on day 56, * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Fig. 6. Mean ± SD of A) IGF-I, B) BMP-2, C) BMP-7 and D) Wnt10b expression of the study groups, using ANOVA and LSD tests on 
day 35, * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
98 MM. Vashghani Farahani et al. Veterinary Research Forum. 2019; 10 (2) 93 - 100 
 
stimulation of mature osteoclasts. They postulated that 
PTX might be of importance for the management of OP and 
suggested performing long-term studies, in order to 
achieve a clear explanation about the role of cyclic 
adenosine monophosphate (cAMP) in bone resorption.34 
For the first time, the results of the current study 
showed that PTX significantly enhanced bone formation 
by healing fractures in OVX rats, both 21 and 56 days after 
administration. In addition, PTX showed antiresorptive 
effect which had a role in decreasing the osteoclast 
numbers. Previous in vitro studies have demonstrated that 
PTX stimulates cellular and molecular paths of bone 
formation and differentiation of osteogenic pioneer cells 
toward an osteoblastic phenotype.35 Consistent with these 
results are those described by Rawadi et al., showing a 
positive effect of PTX on osteoblastic differentiation in 
vitro, using two mesenchymal stem cell lines.36 
Several animal models of inflammation and clinical 
evidences indicate that tumor necrosis factor alpha (TNF-
α) plays a major role in bone loss.37 Kimble et al. revealed 
an increase in bone marrow TNF-α levels in OVX mice.38 
The inhibitory effect of PTX on TNF-α production by various 
cells has been reported.39,40 Our in vivo study for the first 
time showed that PTX administration has significantly 
increased the total bone callus volumes after 21 days and 
even 56 days in OVX rats. Putting all the information 
together, it could be concluded that the suppression of 
TNF-α production by PTX might prevent bone mass 
reduction or reverse OP by increasing the bone mass. The 
mechanism through which PTX decreases TNF-α level 
may be attributed to its capacity to increase cAMP.41  
The PTX is a phosphodiesterase (PDE) inhibitor which 
decreasing the intracellular cAMP and/or cGMP levels.34 
The inhibition of PDE leads to intracellular release and 
therefore increases the levels of cyclic nucleotides, such as 
cAMP and/or cGMP.35 The PTX is an inhibitor of those 
enzymes,34 and could regulate the intracellular cAMP 
accumulation and could affect proliferation and 
differentiation of osteoblasts in a normal situation, leading 
to an increase in bone volume.27 Therefore, the 
administration of PDE-inhibiting compounds such as PTX 
may have the potential to increase bone mass by elevating 
intracellular c-AMP levels.41 Because cAMP action is 
complex34 and also OP is a compromised disease, it is 
difficult to explain and speculate about the possible 
physiological roles of our findings. 
Another possible mechanism by which PTX might 
modify the bone formation is by participating in the 
signaling pathway for BMPs. The BMPs are the proteins 
with the capacity to induce mesenchymal stem cells to 
differentiate into osteoblastic or chondrocytic lineage.42 
Elevated intracellular cAMP level in BMP-replying cells 
augments, BMP influences the cells, and enhances their 
differentiation in normal circumstances,43 which 
consequently facilitates the bone formation. More studies 
 
 are required, in order to find out the precise details of the 
pharmacological mechanism of the PTX related to the bone 
formation. Interestingly, in the current study only in the 
ALN treatment, the expression of IGF-I, BMP-2, BMP-7 and 
Wnt10b have been increased on day 35 post-surgery. 
Consequently, PTX+ALN treatment, and Sham have 
increased the trabecular bone volume, compared to the 
PTX group on day 56. However, a combination of PTX + 
ALN administration has stimulated both osteoblast 
number and trabecular bone volume, 56 days after 
fracture induction. Considering the importance of cortical 
bone volume in the bone strength,44 it seems a 
combination of PTX + ALN is more effective than ALN 
alone, in bone healing from a histological point of view. 
Based on the densitometric and biomechanical 
analysis, administration of PTX increased the density of 
radiological images and biomechanical parameters of the 
femurs and spinal bones in a dose-dependent manner 
(30.00 mg kg-1 to 300 mg kg-1).17,32,34 The results of this 
study did not support the dose of 200 mg kg-1 of PTX, as a 
promising intervention for the prevention or treatment of 
OP. However, the other doses of PTX might be beneficial in 
treating fractures in patients with the presence of 
underlying OP. Aydin et al. concluded that PTX accelerated 
healing process histologically in the early phases of the 
fracture healing. The authors reported that this process 
decreases in the long-term. Moreover, infection which was 
determined histologically was numerically higher in the 
PTX group although there was no statistically significant 
difference between this group and controls.18 The exact 
mechanism by which PTX modulates the bone formation 
remains unclear and may be attributed to the 
pharmacologic effects of the drug.21  
It is concluded that PTX, ALN, and PTX+ALN had anti-
resorptive effect in OVX rats on 21 days and 56 days post-
surgery, compared to the control and sham groups. The 
PTX administration has increased extracellular matrix, 21 
and 56 days post-surgery, compared to the other groups. 
PTX+ALN administration has increased cortical bone 
volume on day 21 and stimulated osteocytes, and osteoblast 
numbers, compared to the control and sham groups on 
day 56. ALN treatment has significantly increased the 
expression of IGF-I, BMP-2, BMP-7 and Wnt10b genes 35 
days after the experimentally induced fracture in OVX rats. 
Further studies are necessary in order to demonstrate the 
positive effect of PTX administration in the process of 
fracture healing in osteoporotic animals. 
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